Amarantus Diagnostics, a neurology-focused diagnostics company
developing diagnostic tests for multiple sclerosis and Alzheimer's
disease and a wholly-owned subsidiary of Amarantus Bioscience
Holdings, Inc. (OTCQX:AMBS), announced that it has established a
Strategic Advisory Committee (SAC). Three seasoned, results-driven
life science and healthcare industry leaders with expertise in
commercializing molecular diagnostics have been appointed to focus
on advancing and deriving the full value of the company's
diagnostics business: Philippe Goix, Ph.D., MBA; Steven T. Guillen,
MBA; and Brian E. Ward, Ph.D.
"Establishing an advisory committee tasked with completing and
executing a robust value creation strategy for Amarantus
Diagnostics has been an important objective in order to drive a
significant return on the investment in Amarantus Diagnostics that
we have made over the last three years," said Gerald E.
Commissiong, President & CEO of Amarantus Bioscience Holdings.
"This team of advisors has a proven track record of strategically
extracting commercial profitability by advancing companies and
their products through a robust commercialization pathway. These
skills will be instrumental as we mature the neuro-diagnostics
business into a powerhouse in the life sciences industry."
Dr. Goix commented, "Amarantus Diagnostics has groundbreaking
neuro-diagnostic tools which may ultimately be game-changers for
the diagnosis of multiple sclerosis (MS) and Alzheimer's disease
(AD). I am excited to help the team finalize the commercial plans
for the company's MSPrecise® diagnostic for MS which has
significant near-term revenue potential. Additionally, the recent
data presented at AAIC validating the LymPro Test® raises its
potential importance as one of the fundamental diagnostic tools in
Alzheimer's drug development for use in biomarker-supported
selection of AD patients for clinical trials, and we will be very
focused on optimizing IUO marketing and CLIA strategy for LymPro.
Both MSPrecise and LymPro are key diagnostic assets with great
potential for improving the investigational and commercial
paradigms for the diagnoses of MS and AD."
Dr. Goix has over 15 years of international experience in
strategic operations and commercialization focused on building
companies with diagnostic tool technology platforms. He is the
former President and Chief Executive Officer of Singulex, Inc., a
commercial healthcare delivery and diagnostics company focused on
providing assay-based clinical diagnostics services to physicians
for chronic disease management. At Singulex Dr. Goix was
responsible for raising over $70M of equity capital, advancing the
company into an IPO process and driving revenue to over $60M
annually. He was also the founder of Guava Technologies, Inc.,
where he served as a director, President and CEO, and Chief
Technical Officer. While at Guava, Dr. Goix raised $27M in equity
capital and led a team that successfully launched Guava's
profitable whole-cell analysis system.
"I believe MSPrecise will be an important assay for physicians
in identifying patients with relapsing-remitting multiple
sclerosis, especially given the high rate of misdiagnosis of this
chronic and extremely debilitating disease. I look forward to
providing the leadership and guidance towards enhancing the
strategy to move MSPrecise forward into a CLIA-enabling validation
studies as an example of how next generation sequencing (NGS) can
make meaningful and valuable improvements to diagnostic standards
in significant indications," added Dr. Ward.
Dr. Ward has over three decades of experience in the life
sciences industry and has created multiple fully accredited
clinical diagnostic laboratories from conception to successful
operation in highly competitive markets in numerous diagnostic
categories. He is the Founder and Principal at Advantage Genomics,
a private consulting firm that provides strategic and tactical
consulting services within the biotechnology sector with expertise
in the discipline of medical diagnostics. Formerly, Dr. Ward was
President and CEO of diaDexus, a company with a demonstrated record
revenue performance focused on development and commercialization of
proprietary diagnostic products addressing unmet needs in
cardiovascular disease. Prior to diaDexus he was the Chief
Operations Officer and Executive Vice President at On-Q-ity Inc., a
company dedicated to developing a new scientific diagnostics
platform to improve cancer care. Dr. Ward was previously Senior
Vice President, Development, at Genomic Health and served as Senior
Vice President of Medical Genetic Services and Operations at Myriad
Genetics.
Mr. Guillen is a market and customer-driven biotech/diagnostic
executive with a successful track record of creating winning
marketing strategies in highly competitive medical device,
pharmaceutical, specialty pharmaceutical, and diagnostic kits and
services environments. He is the former President and Chief
Executive Officer of MedX Health Corporation, a leading medical
device company focused on non-invasive diagnostic devices for skin
cancer, where he successfully developed and executed strategies to
re-invigorate growth. Prior to MedX he was the Chief Executive
Officer of OXIS International, Inc., where he led the turnaround of
an asset rich publicly-traded company with products in diagnostics,
therapeutics, and nutraceuticals to grow existing product revenues
from $2M to $6M in his first year, acquired a private diagnostic
company and directed the merger of the two organizations.
Mr. Guillen concluded, "The advancement of Amarantus
Diagnostics' leading assets, MSPrecise and LymPro, will enable us
to expand our portfolio and begin to unlock further potential with
the Georgetown blood-based biomarkers for Alzheimer's and memory
loss. Success in navigating through the regulatory and commercial
pathways for these exciting products will enable the company to
realize the inherent value in these assets and emerge as a premier
diagnostics company that addresses the significant shortcomings
that exist in accurately diagnosing and treating these devastating
diseases where early intervention could have an important impact on
individuals and their families."
Amarantus BioScience Holdings previously disclosed that it is
exploring strategic options for Amarantus Diagnostics, including
potential sale, co-development or spinoff opportunities, to derive
the full value from its neuro-diagnostics business.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (OTCQX:AMBS) is a biotechnology
company developing treatments and diagnostics for diseases in the
areas of neurology and orphan diseases. AMBS' Therapeutics division
has development rights to eltoprazine, a small molecule currently
in a Phase 2b clinical program for Parkinson's disease
levodopa-induced dyskinesia and with the potential to expand into
adult ADHD and Alzheimer's aggression. The Company has an exclusive
worldwide license to intellectual property rights associated to
Engineered Skin Substitute (ESS), an orphan drug designated
autologous full thickness skin replacement product in development
for the treatment of severe burns currently preparing to enter
Phase 2 clinical studies. AMBS owns the intellectual property
rights to a therapeutic protein known as
mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is
developing MANF as a treatment for orphan ophthalmic disorders,
initially in retinitis pigmentosa (RP). AMBS also owns the
discovery of neurotrophic factors (PhenoGuard™) that led to MANF's
discovery.
AMBS' Diagnostics division owns the rights to MSPrecise®, a
proprietary next-generation DNA sequencing (NGS) assay for the
identification of patients with relapsing-remitting multiple
sclerosis (RRMS) at first clinical presentation, has an exclusive
worldwide license to the Lymphocyte Proliferation test (LymPro
Test®) for Alzheimer's disease, which was developed by Prof. Thomas
Arendt, Ph.D., from the University of Leipzig, and owns
intellectual property for the diagnosis of Parkinson's disease
(NuroPro).
For further information please visit www.Amarantus.com, or
connect with the Company on Facebook, LinkedIn, Twitter and
Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2023 to Mar 2024